The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis - 11/08/12
Correspondence to: Mario E. Lacouture, MD, Memorial Sloan-Kettering Cancer Center, Suite 228, 160 E 53rd St., New York, NY 10022.Abstract |
Background |
The overall incidence and risk of nail changes associated with the use of epidermal growth factor receptor inhibitors (EGFRIs) varies widely across the literature.
Objective |
We conducted a systematic review of the literature and performed a meta-analysis to determine the risk of developing nail toxicity among patients receiving EGFRIs.
Methods |
Databases from Pubmed and Web of Science from January 1998 until July 2011 and abstracts presented at the American Society of Clinical Oncology annual meetings from 2004 through July 2011 were searched to identify relevant studies. The incidence and relative risk (RR) of nail toxicity were calculated using random-effects or fixed-effects model depending on the heterogeneity of the included studies.
Results |
A total of 2107 patients from 22 clinical trials were included in this analysis. The overall incidence of all-grade nail toxicity was 17.2% (95% confidence interval [CI]: 13.8%-21.3%), with an RR of 76.94 (95% CI: 40.76-145.22, P < .001). The overall incidence of high-grade nail toxicity was 1.4% (95% CI: 0.9%-2.1%), with an RR of 13.11 (95% CI: 3.73-46.03, P < .001).
Limitations |
The ability to detect and grade nail changes may vary among institutions.
Conclusion |
There is a significant risk of developing nail toxicity in cancer patients receiving EGFRIs. The risk is independent of the underlying agent. Adequate monitoring and early intervention are recommended to prevent debilitating toxicity and suboptimal dosing of EGFRI.
Le texte complet de cet article est disponible en PDF.Key words : cancer, cetuximab, EGFR inhibitor, erlotinib, lapatinib, nail toxicity, panitumumab, paronychia
Abbreviations used : AE, CI, CTCAE, EGFR, EGFRIs, mCRC, NSCLC, RR
Plan
| Funding sources: Dermatology Foundation Career Development Award. |
|
| Conflicts of interest: Dr Lacouture has worked as a consultant for ImClone, Bristol-Myers Squibb, Roche, Pfizer, OSI Pharmaceuticals Inc, and Genentech. Dr Wu serves on the advisory board and as a speaker to Onyx Pharmaceuticals, Novartis Pharmaceuticals, Pfizer Inc, Amgen, and as a speaker for Janssen Pharmaceuticals, Inc. Mr Garden has no conflict of interests to declare. |
|
| Reprints not available from the authors. |
Vol 67 - N° 3
P. 400-408 - septembre 2012 Retour au numéro
Article précédent
- Merkel cell carcinoma: The prognostic implications of an occult primary in stage IIIB (nodal) disease
- Matthew Foote, Michael Veness, Dannie Zarate, Michael Poulsen
- Vulvo-cervico-vaginal manifestations and evaluation of Papanicolaou smears in pemphigus vulgaris and pemphigus foliaceus
- Natasha D. Fairbanks Barbosa, Lana M. de Aguiar, Celina W. Maruta, Valéria Aoki, Miriam N. Sotto, Glaucia H.O. Labinas, Alexandre M. Perigo, Claudia Giuli Santi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?